Acute and chronic effects of thyrotropin-releasing hormone (TRH) on stabilogram in spinocerebellar degenerations.
A single blind cross over trial was conducted of thyrotropin-releasing hormone treatment in 7 patients with spinocerebellar degenerations. Patients received daily 2 mg of thyrotropin releasing hormone intramuscularly during the 2 week treatment period. Acute beneficial effect on stabilogram was demonstrated, but significant therapeutic efficacy in the chronic treatment failed to be demonstrated, though a trend of effectiveness was observed.
D000328:Adult; D002524:Cerebellar Ataxia / Q000188:drug therapy / Q000503:physiopathology; D002526:Cerebellar Diseases / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D005133:Eye Movements / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013118:Spinal Cord Diseases / Q000188:drug therapy* / Q000503:physiopathology; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use*; D013997:Time Factors
D013973:Thyrotropin-Releasing Hormone